Strategic positioning for clinical trial results in 1Q 2022

MyMD has received FDA clearance to commence a Phase 2 clinical trial of MYMD-1 in Sarcopenia (aging)  in 2021 and expects efficacy data by the end of first quarter of 2022. In addition, we expect to advance MYMD-1 into a phase 2 clinical trial for treatment of diabetes, rheumatoid arthritis, and multiple sclerosis. We will also execute studies of Supera-CBD that will enable submission of an Investigational New Drug Application (IND) to the FDA for a Phase 1 clinical trial in epilepsy, addiction, autism and anxiety disorders.

 

  • This field is for validation purposes and should be left unchanged.